Video
Author(s):
“The data is out to about 2 to 3 years now, so…[it’s] a little bit on the immature side, but it's very promising,” says Bilal Chughtai, MD.
In this video, Bilal Chughtai, MD, assesses the success of the iTind system as reported in the study, “Preservation of ejaculatory and erectile function with iTind system for treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia,” presented recently at the 2021 American Urological Association annual meeting. Chughtai is an associate professor of urology, obstetrics and gynecology at Weill Cornell Medicine and an attending urologist at NewYork-Presbyterian Hospital, New York City, New York.